Parliamentary Search

Proceeding contribution from Alan Johnson (Labour) in the House of Commons on Tuesday, 4 November 2008. It occurred during Ministerial statement on NHS Patients (Access to Medicines).

NHS Patients (Access to Medicines)

If the drug company has not applied for this, the same circumstances will apply: the drug has not been NICE-approved, because the company has not applied to have it NICE-approved. However, that does not stop a PCT allowing that drug to be prescribed, which is why the transparent and clear process around PCT exceptional circumstances committees—which is where such matters would rest—is an important part of the Richards review.

Secondary information

Type
Proceeding contribution
Reference
482 c141 
Session
2007-08
Chamber / Committee
House of Commons chamber
Subjects
Access Finance Fees and charges Drugs Private sector NHS Medical treatments Patients Payments National Institute for Health and Care Excellence Consequences of Additional Private Drugs for NHS Care Review
Link
View this Proceeding contribution on www.publications.parliament.uk